Screener
Tango Therapeutics TNGX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's accrued expenses?
- Tango Therapeutics (TNGX) reported accrued expenses of $3.24M in Q1 2026.
- How has Tango Therapeutics's accrued expenses changed year-over-year?
- Tango Therapeutics's accrued expenses increased by 1.9% year-over-year, from $3.18M to $3.24M.
- What is the long-term trend for Tango Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Tango Therapeutics's accrued expenses has grown at a 27.8% compound annual growth rate (CAGR), from $2.65M to $9.05M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Tango Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude